How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pet Euthanasia Market
- By Service Type: In-Clinic Euthanasia, At-Home Euthanasia, Mobile Veterinary Services, Emergency Euthanasia Services
- By Animal Type: Dogs, Cats, Small Mammals (Rabbits, Guinea Pigs), Birds, Reptiles
- By Procedure Method: Intravenous Injection, Intraperitoneal Injection, Inhalant Anesthesia, Oral Sedation
- By End-of-Life Care Options: Sedation and Palliative Care, Immediate Euthanasia, Pre-Euthanasia Sedation, Memorial and Aftercare Services
- By Provider Type: Veterinary Clinics, Specialized Euthanasia Providers, Mobile Veterinary Units, Animal Hospices
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - In-Clinic Euthanasia leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Pet Euthanasia Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Service Type 4
Animal Type 5
Procedure Method 4
End-of-Life Care Options 4
Provider Type 4
Companies profiled
Baxter International Inc.
Zoetis Inc.
Elanco Animal Health Incorporated
Merial (a Boehringer Ingelheim company)
Vetoquinol SA
Dechra Pharmaceuticals PLC
Merial (Sanofi)
Ceva Santé Animale
Virbac
Norbrook Laboratories Ltd
Boehringer Ingelheim Animal Health
Idexx Laboratories Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Zoetis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Elanco Animal Health Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merial (a Boehringer Ingelheim company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Vetoquinol SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Dechra Pharmaceuticals PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merial (Sanofi)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Ceva Santé Animale
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Virbac
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Norbrook Laboratories Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Boehringer Ingelheim Animal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Idexx Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Covetrus Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →PetSmart Inc. (Banfield Pet Hospital)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →VCA Animal Hospitals (Mars
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,051M by 2033 · 4.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- In-Clinic Euthanasia54.6
- At-Home Euthanasia11.9
- Mobile Veterinary Services16.3
- Emergency Euthanasia Services17.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,191M → $1,633M · 4.0%
Europe$830.4M → $1,228M · 5.0%
Asia Pacific$758.2M → $1,038M · 4.0%
Latin America$469.3M → $696.2M · 5.1%
Middle East and Africa$361.0M → $487.8M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.232026
4.262027
4.272028
4.282029
4.292030
4.302031
4.322032
4.312033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.12.9
- Zoetis Inc.14.7
- Elanco Animal Health Incorporated13.6
- Merial (a Boehringer Ingelheim company)6.5
- Vetoquinol SA11.3
- Dechra Pharmaceuticals PLC13.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type24.3%
Animal Type26.1%
Procedure Method14.5%
End-of-Life Care Options20.4%
Provider Type14.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe24.2
- Asia Pacific20.4
- Latin America13.7
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 85 | 86 | 96 | 96 | 95 | 98 | 93 |
| Zoetis Inc. | 79 | 73 | 89 | 80 | 79 | 76 | 79 |
| Elanco Animal Health Incorporated | 69 | 70 | 72 | 84 | 79 | 67 | 74 |
| Merial (a Boehringer Ingelheim company) | 81 | 62 | 67 | 60 | 57 | 71 | 66 |
| Vetoquinol SA | 63 | 75 | 67 | 55 | 68 | 63 | 65 |
| Dechra Pharmaceuticals PLC | 62 | 57 | 48 | 70 | 65 | 66 | 61 |
| Merial (Sanofi) | 49 | 41 | 63 | 49 | 61 | 63 | 54 |
| Ceva Santé Animale | 40 | 39 | 45 | 53 | 54 | 50 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- Zoetis Inc.
- Elanco Animal Health Incorporated
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Zoetis Inc. | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Elanco Animal Health Incorporated | ◐ | − | ◐ | ✓ | ✓ | ◐ |
| Merial (a Boehringer Ingelheim company) | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Vetoquinol SA | − | ✓ | ◐ | ◐ | − | − |
| Dechra Pharmaceuticals PLC | ◐ | − | − | ◐ | − | ✓ |
| Merial (Sanofi) | − | − | ◐ | ◐ | ◐ | ◐ |
| Ceva Santé Animale | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.93
2Zoetis Inc.79
3Elanco Animal Health Incorporated74
4Merial (a Boehringer Ingelheim company)66
5Vetoquinol SA65
6Dechra Pharmaceuticals PLC61
7Merial (Sanofi)54
8Ceva Santé Animale47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.Zoetis Inc.
Challenger1
Strong scale, closing on the leaders.
Elanco Animal Health Incorporated
Contender3
Focused players with pockets of strength.
Merial (a Boehringer Ingelheim company)Vetoquinol SADechra Pharmaceuticals PLC
Niche2
Specialists in a single segment or region.
Merial (Sanofi)Ceva Santé Animale
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Pet Euthanasia Market — a $183M beachhead inside a $2.37B market.
Beachhead (SOM)$183Mobtainable near-term
Serviceable (SAM)$983Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
In-Clinic Euthanasia
Best fit — highest urgency & budget in Service Type.
Economic buyer79 fit
At-Home Euthanasia
Strong fit — clear ROI and a fast path to value.
End user68 fit
Mobile Veterinary Services
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Animal Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Procedure Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pet Euthanasia Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation12%
Closed-won6%
$11.8KCAC
$56KLTV
4.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pet Euthanasia Market is a resilient opportunity — $4.03B by 2033, compounding at 4.8%.
TAM · 2025$2.77Btoday
TAM · 2033$4.03Bforecast
CAGR4.8%2027–2033
Cumulative$30.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.03BTotal addressable market
SAM$1.51BServiceable available market
SOM$290MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.8% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.03BLarge & growingTAM by 2033 at 4.8% CAGR
$1.51BServiceable nowreachable with today’s model
$290MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.14BBear3.1% CAGR
$4.03BBase4.8% CAGR
$5.16BBull6.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Animal Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pet Euthanasia Market — a $3.30B market by 2033. Plan: grow share from 8.5% to 14.7%.
Market size · 2033$3.30Btotal addressable
Market CAGR7.3%2027–2033
Target share14.7%from 8.5% today
Revenue ambition$484Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 14.7% | On track |
| Revenue | $256M | $484M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 34.7% | 45.9% | At risk |
| Customer retention | 91.1% | 94.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Animal Type capability
A defensible second engine — invest in Animal Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Animal Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $58M capacity & capability investment
- Greenlight bolt-on M&A in Animal Type
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pet Euthanasia Market conversation — a $2.57B market you can size, segment and defend in minutes.
Market size · 2033$2.57Btotal opportunity
Growth10.2%CAGR to 2033
Addressable buyers1,437+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 4 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Baxter International Inc.Zoetis Inc.Elanco Animal Health IncorporatedMerial (a Boehringer Ingelheim company)Vetoquinol SADechra Pharmaceuticals PLCMerial (Sanofi)Ceva Santé Animale+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pet Euthanasia Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pet Euthanasia Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pet Electronic Thermometer Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportPet Ear Infection Treatment Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPet Ear Drops Market
Market size, share, segmentation and regional forecast.
$579M market · 2025 base year
View reportPet Ear and Eye Drops Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportPet Drug Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportPet Drug and Vaccine Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPet Dog DNA Test Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportPet DNA Vaccines Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportPet DNA Test Service Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportPet DNA Test Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportPet DNA Test Kits Market
Market size, share, segmentation and regional forecast.
$833M market · 2025 base year
View reportPet DNA Testing Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.